KLRK1 and cervical cancer: This first study of hydralazine/valproic acid in cervical cancer shows HLA and CTL boosts, with potential to reactivate antigens like MAGE/GAGE and NKG2D ligands, linking to ovarian strategies enhancing immunotherapy via TIME modulation [140, 141].